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A B S T R A C T
Background: The use of combined oral contraceptives has been associated with an increased risk of
adverse cardiovascular events. Whether these drugs alter cardiac autonomic nervous system control is
not completely determined.
Objective: To evaluate the effect of a contraceptive containing 20 mcg of ethinyl estradiol and 3 mg of
drospirenone on the heart rate variability, baroreﬂex sensitivity and blood pressure of healthy women.
Study design: Prospective controlled trial with 69 healthy women allocated in two groups: 36 volunteers
under oral combined contraceptive use and 33 volunteers using of non-hormonal contraceptive
methods. Subjects were tested before the introduction of the contraceptive method and 6 months after
its use. For data acquisition, we used continuous non-invasive beat-to-beat blood pressure curve
recordings. Multiple ANOVA was used to determine differences between groups and moments and p <
0.05 was considered statistically signiﬁcant.
Results: At baseline, there were no differences in demographic and autonomic parameters between
groups. Comparing cardiac sympatho-vagal modulation, baroreceptor sensitivity and blood pressure
measurements between baseline and after 6 months, no signiﬁcant difference was detected in each
group or between groups.
Conclusion: A contraceptive containing 20 mcg of ethinyl estradiol and 3 mg of drospirenone causes no
signiﬁcant changes in clinical, hemodynamic and autonomic parameters of normal women.
 2014 Elsevier Ireland Ltd. All rights reserved.
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Since their introduction in the 1960s, the use of combined
hormonal oral contraceptives (COCs) has been related to an
increased risk of cardiovascular disease [1]. The exact mechanism
by which COCs may increase cardiovascular risk is still unclear,
although it is most likely multifactorial and complex. The
understanding of this mechanism is extremely important consid-
ering the large number of women taking COCs: it is estimated that
nearly 20% of women of reproductive age are currently prescribed
oral contraceptives [2].* Corresponding author at: Avenida Dr. Ene´as Carvalho de Aguiar, 255, 10 andar
ICHC, Cerqueira Ce´sar, Sa˜o Paulo, CEP-05403-000.
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http://dx.doi.org/10.1016/j.ejogrb.2014.01.006Many studies have demonstrated increases in blood pressure in
women after chronic use of COCs [2,3]. In addition to the changes in
blood pressure, other factors have been proposed and investigated
to explain the COC-associated increase in cardiovascular risk, such
as changes in insulin resistance, lipid proﬁle and endothelial
function, as well as the development of coagulation disorders and,
more recently, changes in the functioning of the autonomic
nervous system [2,4]. The latter change is considered one of the
most important mechanisms underlying the pathogenesis of
hypertension and cardiovascular disease [5,6].
Few studies have been conducted to examine the impact of
hormonal contraception on heart rate variability and on the
autonomic nervous system, and no prospective, controlled study
has been published to date [7–10].
When evaluating the different types of contraceptives,
attention has been drawn to a formulation containing drospir-
enone (DRSP), a progestin derived from spironolactone with
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in normotensive women show that the use of DRSP was associated
with favorable effects on the cardiovascular system [11,12].
Additionally, a possible mechanism by which COCs could increase
blood pressure is via activation of the renin-angiotensin system,
and itis known that DRSP, like endogenous progesterone,
attenuates the vascular effects of estrogen and can therefore
block this effect [13]. Furthermore, a recent study has shown an
anti-inﬂammatory action of DRSP with potential cardiovascular
protective effect [14]. On the other hand, recent studies also
suggest the possibility of DRSP having greater thrombotic risk,
while other studies show a similar risk to other contraceptive pills
[15,16].
Therefore, the objective of this study was to evaluate the effect
of a contraceptive consisting of ethinyl estradiol (EE) and DRSP on
heart rate variability and the autonomic nervous system, which is
important for evaluating the safety of these drugs.
2. Methods
The volunteers in this study were 80 healthy women recruited
from primary and secondary health care facilities. Each participant
underwent medical screening by a physician and provided written
and oral consent. This study was approved by the Research Ethics
Committee, General Hospital, School of Medicine, University of Sa˜o
Paulo. To be included, subjects were normotensive healthy
women, without any chronic disease, age between 20 and 40
years, with regular menstrual cycles and having used no hormonal
contraceptives for at least 6 months prior to the start of the study.
Exclusion criteria were a positive pregnancy test, a category 3 or 4
classiﬁcation according to WHO’s Medical Eligibility Criteria for
contraceptive use [17], current smoking, obesity, fasting glucose
above 100 mg/dL, insulin resistance or lipid proﬁle abnormalities.
2.1. Sample size calculation
The minimum size of the sample was determined from a pilot
sample containing ten observations for each group. Six variables
were used to determine the sample size: four variables that
concerned autonomic tone and two hemodynamic variables.
Considering that a type I error of 0.05 and a power of 0.8 was
necessary to detect a difference between the two groups of 20% on
average, the minimum sample size per group necessary for
the study of each of these six variables was 32 patients. The
calculations were based on the equation of Diggle et al. [18].
2.2. Experimental design
All women selected were eligible for both contraceptive
methods. However, after being counseled regarding the advan-
tages, disadvantages and side effects of each contraceptive
method, the volunteers were allowed to freely choose the type
of contraception they wanted to use: COCs or non-hormonal
methods. Therefore, women who agreed to participate in the study
were allocated into two groups: (1) users–women who chose to
use a COC containing 20 mcg EE and 3 mg DRSP, with 24 days of
active pills and a 4 day pill-free interval (n = 40), and (2) nonusers–
women who chose to use a non-hormonal method of contraception
(condoms or copper IUD) (n = 40).
All volunteers were evaluated during the same menstrual cycle
phase: follicular phase at baseline for both groups; follicular phase
in the follow-up of the control group; high hormonal phase in the
contraceptive group. All studies were conducted in a temperature-
controlled room, and the subjects were instructed to abstain from
exercise, caffeine, and alcohol for 12 h before testing. All
examinations were performed during the same time of day forboth trials. Data acquisition was performed with the volunteer in
the supine position for 15 min. The analysis was performed using
the ﬁnal 5 min of each acquisition period.
2.3. Evaluation methods for body mass index, blood pressure and
hemodynamic variables
2.3.1. Body mass index (BMI)
BMI was obtained using measures of weight and height of each
subject acquired during basal evaluation and at the end of the
study.
2.3.2. Ofﬁce blood pressure measurement
Blood pressure was obtained using the auscultatory method
with a calibrated mercury sphygmomanometer following the
American Heart Association technique recommendations. Three
measurements were made and the value considered was
the average of the measurements [19].
2.3.3. Hemodynamic variables
The pressure curves were obtained on a beat-to-beat basis,
continuously and noninvasively, with the Finometer1 device
(FMS, Finapres Medical System, Anhem, The Netherlands). This
device was equipped with BeatScope software, which generated
data on the systolic blood pressure (SBP), diastolic blood pressure
(DBP), and mean blood pressure (MBP); heart rate (HR); cardiac
output (CO); and total peripheral resistance (TPR), based on values
derived from the arterial pressure curve and information on
patient age, gender, weight and height. Studies in the literature
regarding the validation of this method using direct and invasive
measurements have demonstrated its accuracy and that the values
obtained can be superimposed onto the curve of brachial artery
pressure [20–22].
2.4. Heart rate variability and autonomic nervous system parameters
The pressure curves obtained with the Finometer1 device were
simultaneously recorded in another computer equipped with
biological signal acquisition and signal conversion software (AT/
MCA-CODAS; DATAC Instruments Inc., Akron, Ohio, USA). The
sampling frequency of the signals was 1000 Hz. The stored signals
were subsequently subjected to an analysis routine that provided
values for HR variability, blood pressure, and spontaneous
baroreﬂex sensitivity. After these signals were pre-ampliﬁed
(General Purpose Ampliﬁer; Stemtech, Inc., 4-GPA), they were
converted from analog to digital and then stored for later analysis.
Each heart beat was identiﬁed by the use of a specialized algorithm
implemented in Matlab MT (MATLAB 6.0, Mathworks) that
automatically detects systolic and diastolic pressure waves. The
pulse interval or R-R interval was calculated as the difference
between the beginning and end points of the cycle (t1  t0).The
power spectral density of the R–R interval was obtained by fast
Fourier transformation using Welch’s method over 16,384 points
with a Hanning window and 50% overlap. The spectral bands for
humans were deﬁned according to references from the literature;
speciﬁcally, the spectral bands used were 0.0–0.04 Hz (very low
frequency, VLF), 0.04–0.15 Hz (low frequency, LF), and 0.15–0.4 Hz
(high frequency, HF) [20–22].
2.5. Statistical analysis
The variables of interest in both groups were assessed at
baseline and after 6 months of use of the chosen contraceptive
method. Statistical analysis of the data was carried out with R 2.9
(R Foundation for Statistical Computing, Vienna, Austria) and SAS
9.1 (SAS Institute, Cary, NC) softwares.
Table 1
Demographic and clinical parameters at baseline.
Variable Users (n = 36) Nonusers (n = 33) P value
Age (years) 28.75  1.07 30.30  0.95 .28
BMI (kg/m2) 25.32  0.62 24.78  0.59 .53
AC (cm) 85.29  2.59 85.00  1.58 .92
SBP (mm Hg) 112.5  2.01 115.5  2.00 .3
DBP (mm Hg) 66.49  1.23 67.12  1.53 .75
Values are expressed as the mean  SE. Statistical signiﬁcance was set at P < .05. BMI-
body mass index; AC- abdominal circumference; SBP- systolic blood pressure; DBP-
diastolic blood pressure.
Table 3
Autonomic variables at baseline and after 6 months of contraceptive use.
Variable Group Baseline After 6 months
PI(ms) Users 841.9  21 858.9  19
Nonusers 857.2  17 863.4  14
SD(ms) Users 51.9  3.6 54.4  2.75
Nonusers 59.9  3.8 58.7  3.1
NN50 Users 72.1  8.37 83.3  8.9
Nonusers 98.1  10.6 99.2  9.3
RMSSD (ms) Users 46.1  3.8 47.4  3.3
Nonusers 54.3  4.3 53.6  3.8
VAR RR (ms) Users 3157  419.5 3228  329.9
Nonusers 4066  524.1 3765  391.8
%LF Users 44.01  2.4 39.57  1.9
Nonusers 40.48  2.2 40.56  2.3
%HF Users 46.87  2.4 42.27  2.1
Nonusers 43.9  2.7 43.7  2.7
LF/HF Users 1.11  0.1 1.15  0.1
Nonusers 1.14  0.1 1.19  0.1
VAR PAS (mm Hg) Users 27.6  3.1 26.8  2.6
Nonusers 29.4  2.8 38.7  6.5
PWT (ms2) Users 17.8  2.0 19.7  2.0
Nonusers 21.4  2.4 25.4  3.2
LF Users 6.5  0.9 6.8  0.9
Nonusers 7.9  1.0 8.3  0.8
Alpha LF Users 11.4  0.8 11.8  0.9
Nonusers 11.7  0.9 11.2  0.8
Values are expressed as the meanS.E. Statistical signiﬁcance was set at P < .05. All
parameters with p > .05. PI–pulse interval; SD–standard deviation of all normal to
normal intervals; NN50–numbers of pairs of adjacent normal to normal intervals
differing by more than 50 ms in the entire record; RMSSD–the square root of the mean
of the sum of the squares of differences between adjacent normal to normal intervals;
VAR RR–RR interval variability; LF–power in low frequency range; HF–power in high
frequency range; VAR PAS–systolic arterial blood pressure variability; PWT–variances
of all normal to normal intervals; Alpha LF–low frequency range slope of the linear
interpolation of the spectrum in a log-log scale.
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clinical parameter variable at baseline using Student’s t test and
likelihood ratio tests based on a generalized linear model with a
gamma distribution, or the Mann–Whitney test, depending on the
characteristics of each variable [23–25]. The mean of each variable
was analyzed as a function of time and group using the scores from
the tests of generalized estimating equation models or nonpara-
metric tests (Mann–Whitney test and Wilcoxon rank sum test)
[26].
3. Results
There were initially 153 healthy women screened, but only 80
were selected for this study, with 40 in each group. In the group
that used hormonal contraceptives, four subjects were excluded
(three subjects who did not undergo follow-up and one subject for
whom data analysis was not possible). In the control group, seven
subjects were excluded (ﬁve subjects who did not undergo follow-
up and two subjects for whom data analysis was not possible).
Table 1 displays the results concerning the clinical parameters
at baseline. Despite the nonrandomized nature of the groups, our
results showed that the clinical parameters of women who chose
to use the COC were not signiﬁcantly different from those who
opted for non-hormonal methods.
The results of the statistical tests examining differences in the
clinical and hemodynamic parameters between baseline and
6 months after contraceptive use are presented in Table 2. There is
no evidence of any change in any of the clinical and hemodynamic
variables examined over the course of 6 months of COC use.Table 2
Clinical and hemodynamic parameters at baseline and after 6 months of
contraceptive use.
Variable Group Baseline After 6 months
BMI (kg/m2) Users 25.32  0.62 25.30  0.66
Nonusers 24.78  0.59 25.14  0.59
AC (cm) Users 85.29  2.59 84.84  2.79
Nonusers 85.00  1.58 85.92  1.89
SBP (mm Hg) Users 112.5  2.01 111.6  1.79
Nonusers 115.5  2.00 117.13  2.3
DBP (mm Hg) Users 66.49  1.23 65.01  1.04
Nonusers 67.12  1.53 67.47  1.57
MBP (mm Hg) Users 85.39  1.55 84.10  1.24
Nonusers 87.29  1.68 88.41  1.77
HR (bpm) Users 74.31  1.86 74.25  1.67
Nonusers 71.83  1.07 71.25  1.32
CO (l/min) Users 5.66  0.16 5.72  0.20
Nonusers 5.84  0.23 5.81  0.18
TPR (nu) Users 0.93  0.03 0.94  0.04
Nonusers 0.91  0.03 0.94  0.03
Values are expressed as the meanS.E. Statistical signiﬁcance was set at p < .05. All
parameters with p > .05. BMI–body mass index; AC–abdominal circumference; SBP–
systolic blood pressure; DBP- diastolic blood pressure; MBP- mean blood pressure;
HR–heart rate; CO–cardiac output; TPR–total peripheral resistance.With respect to blood pressure, the results showed no
signiﬁcant difference in the SBP or DBP values between the COC
group and the control group.
The results of the tests of interest for autonomic variables are
presented in Table 3. The results show that the autonomic
parameters were not signiﬁcantly different between baseline and
6 months after initial evaluation in either group. No differences
between the groups were observed at either time point.
Finally, the baroreﬂex sensitivity which was assessed using the
alpha index was also similar between the groups and over time.
4. Comments
The main ﬁnding of our study was the demonstration of no
signiﬁcant alterations in blood pressure, heart rate variability and
baroreﬂex sensitivity of healthy women during a 6 month period of
use of a COC containing EE and DRSP. Thus, we could determine in a
prospective clinical trial that this form of contraception does not
cause an increase in blood pressure or alter other cardiovascular
autonomic parameters in otherwise healthy women.
There is a suspicious relationship between COC use and
increased cardiovascular risk [1,2]. A possible mechanism of
action is a change in sympathetic tone, which has been
demonstrated to be related to increased cardiovascular risk in
many clinical situations [5,6]. This hypothesis has not been well
studied to date and was therefore the focus of this study.
A review of the literature revealed no consensus on the effects
of contraceptives on autonomic tone. Minson et al. [7] assessed the
sympathetic and cardiovagal baroreﬂex sensitivities of nine
women, comparing the placebo to the active phase of an oral
contraceptive. The sympathetic baroreﬂex sensitivity was assessed
by measuring the changes in the sympathetic activity of the
peroneal nerve and in DBP in response to the administration of
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ences in resting sympathetic activity and plasma levels of
norepinephrine were observed between the two phases of the
contraceptive in this study, but sympathetic and cardiovagal
baroreﬂex sensitivities and the mean arterial pressure were higher
in the placebo phase. The authors concluded that the sympathetic
response changes over the contraceptive cycle [7]. In contrast, a
study published in 2010 assessed the muscle sympathetic nerve
response in the peroneal nerves of 12 women to orthostatic
stimulation, and no differences were observed between the active
and placebo phases [8].
In these studies, the small sample size and lack of a control
group may have inﬂuenced the detection of changes and hindered
the analysis. In 2013 Cagnacci et al. evaluated the impact of
6 months use of EE/DRSP on blood pressure and heart rate on
normotensive women [27]. Ambulatory blood pressure monitoring
(ABPM) was recorded for 41 h, and the last 24 h were used for
analysis. The study did not demonstrate signiﬁcant differences in
blood pressure levels, but heart rate had a small but signiﬁcant
increase (4 bpm). Our study and that of Cagnacci et al. share some
similarities: both used same combination of COC, are prospective,
and had a 6 month period of observation. Our study, however,
analyzed BP and HR recorded in a more stable and reproducible
condition compared to method used by the other study, since
ABPM is inﬂuenced by day-by-day activity. Furthermore, we add
data on the effect of oral contraceptive with EE+drospirenone on
cardiac autonomic modulation, which is known as an independent
marker of cardiovascular risk. Therefore, these two studies are
complementary regarding to the inﬂuence of drospirenone on
hemodynamic parameters of normotensive women.
We chose to study only one type of contraceptive to decrease
the possibility of increasing variability by using different types of
hormonal contraceptives with different hormonal actions, doses
and effects. The reasons for choosing drospirenone have been
already described in the introduction. In our study, we found that
the COC used caused no changes in mean body weight and a small,
non-signiﬁcant decrease of approximately 1 mm Hg in both mean
SBP and DBP, which is consistent with the results of other studies
discussed above [11,12].
Despite the lack of data in the literature, it was felt that six
months would be sufﬁcient to evaluate the possible chronic effect
of the contraceptive use on the parameters evaluated, as can be
observed in another recent study [27]. Although we know that
autonomic changes occur quickly, we believe that the comparison
only with the placebo period of contraceptive use is insufﬁcient
and that analysis that takes into account the autonomic proﬁles
of women before the introduction of COCs is more reliable. This
idea is consistent with the results of a study showing that blood
pressure does not decrease during the 7 day pill-free period
compared with the active phase [3].
All women were examined in the same phase of the menstrual
cycle. Despite conﬂicting results, most studies show that there are
small autonomic variations over the course of the cycle [9,28,29].
Thus, by systematizing the time of examination, we prevented the
possibility of the results being inﬂuence by physiological hormonal
changes.
Finally, we observed similar values when comparing our
results, especially those concerning autonomic parameters such
as the spectral band patterns, with other studies on healthy,
premenopausal women, thus demonstrating the reproducibility of
the data acquired [28]. Therefore, we believe that our results are of
great reliability.
One potential criticism of the study is the lack of randomization.
To lessen the effect of this potential limitation, however, the data
analysis was performed by a blinded examiner. Moreover, even if
randomized, the study would not be double-blinded, as thesubjects were aware of which contraceptive method they used
(hormonal contraceptive versus intrauterine device). Finally,
strength of the study is comparing the woman with herself, which
is independent of randomization.
The volunteer loss was slightly lower in the hormonal
contraceptive group, most likely because these women received
medication upon every return to the treatment facility, which
increased motivation and adherence to treatment protocol.
However, when evaluating the results and comparing the groups
after taking participant losses into account, no signiﬁcant
differences between groups were observed with regard to various
characteristics; therefore, we considered the groups comparable.
In conclusion, this study found no effects of the use of
contraceptives containing EE and DRSP on blood pressure or on
several autonomic parameters during the 6 month evaluation.
Therefore, at least for the formulation studied, our results
contradict the hypothesis that increased sympathetic tone is
involved in the contraceptive-associated increase in cardiovascular
risk, and suggest that this medication may be a favorable choice for
people who have already experienced autonomic changes, such as
hypertensive and obese women. We believe, however, that
because of the large epidemiological and clinical relevance of
the potential effect of hormonal contraceptives on cardiovascular
risk, new studies should be conducted to study the possible
mechanisms involved. Only after these studies are complete will it
be possible to clearly deﬁne the safety indications of this
contraceptive method in various populations.
Condensation
In this prospective clinical trial, a contraceptive containing
drospirenone did not cause an increase in blood pressure or alter
other cardiovascular autonomic parameters in healthy women.
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